Category: Alzheimer’s

Family Caregivers Find Support on #dementia TikTok

The TikTok hashtag “dementia” has billions of views. Caregivers of people with Alzheimer’s and other dementias have been using the site to swap tips and share the burdens of life with dementia.

KHN’s ‘What the Health?’: Leaked Abortion Opinion Rocks Washington’s World

The unprecedented early leak of a Supreme Court draft opinion that would overturn the landmark abortion-rights ruling Roe v. Wade has heated the national abortion debate to boiling. Meanwhile, the FDA, after years of consideration, moves to ban menthol flavors in cigarettes and cigars. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Shefali Luthra of the 19th, and Jessie Hellmann of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Paula Andalo, who wrote the latest KHN-NPR “Bill of the Month” episode about a family whose medical debt drove them to seek care south of the border.

Patients Divided Over Alzheimer’s Drug: Is It a ‘Risk I’m Willing to Take’ or Just a ‘Magic Pill’?

Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.

Watch: Seniors Share How They’ve Made It Through the Pandemic

Nine seniors from across the country talk frankly about feeling alone and constrained, missing church, and family routines. They also share newfound hope and discoveries that arose from the crisis.

Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug

An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.

KHN’s ‘What the Health?’: Dealing With Drug Prices

Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.

KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’

Can’t see the audio player? Click here to listen on Acast. You can also listen on Spotify, Apple Podcasts, Stitcher, Pocket Casts or wherever you listen to podcasts. Sen. Joe Manchin (D-W.Va.) dashed the hopes of President Joe Biden and congressional Democrats for passage of the giant “Build Back Better” bill before the end of […]

Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?

The condition can be an early signal of Alzheimer’s disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.

Minister for Seniors at Famed Church Confronts Ageism and the Shame It Brings

Lynn Casteel Harper, a minister at the interdenominational Riverside Church in New York City, discusses the spiritual dimension of aging.

Facing Headwinds on New Alzheimer’s Drug, Biogen Launches Controversial Campaign

The makers of Aduhelm, a drug approved last month despite concerns raised by experts about its effectiveness, have launched a website and ads designed to urge people who are worried about their memory to ask doctors about testing. But some health advocates say it is misleading because some memory loss with aging is normal.